Plain-English translation of NCT06741150 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing an experimental medication called NWRD09, given as injections into the muscle, for women with HPV-16 (a virus linked to cervical cancer). The trial includes two groups: women with precancerous changes in the cervix, vagina, or vulva, and women with advanced cervical cancer that has progressed despite previous treatments. Researchers want to understand how safe this treatment is and what dose works best.
Many women with HPV-related cervical disease need better treatment options, especially those whose cancers have come back or spread after standard therapy. This medication aims to help these patients by harnessing the body's immune system to fight HPV-infected cells.
You would receive injections of the medication directly into your muscle at different dose levels to find the safest and most effective amount. The study is small and early-stage, so you'd be carefully monitored with blood tests and imaging scans to watch for side effects and signs that the treatment is working. You would need to complete all scheduled visits and follow-up exams as outlined in the study plan.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Sponsor
Newish Technology (Beijing) Co., Ltd.
Enrollment target
~18 participants
Started
June 2024
Primary completion
December 2025
Age range
18 Years – 60 Years
Sex
Female only
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yong Mao, M.D.
Newish Technology (Beijing) Co., Ltd.